Ayoxxa Biosystems GmbH, a Cologne, Germany-based biotechnology company, closed a €2.3m third tranche of Series B financing.
Backers included BioMedPartners and Grazia Equity.
The company, which has now raised €11.3m in 2014, intends to use the funds to continue its production ramp-up efforts as well as to speed-up global commercial activities.
Led by Dr. Andreas Schmidt, CEO and Co-founder, and newly named CFO Andreas Richter, Ayoxxa Biosystems has developed a proprietary technology platform for multiplex protein analysis.
The company also has operations in Singapore.
FinSMEs
03/12/2014